Drugs.com Clinical Trial ResultsOriginal article
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
RegulatoryVarsetatug masetecanPositive
AI Analysis
Summary
CytomX Therapeutics announced that the FDA has granted Fast Track designation for varsetatug masetecan (Varseta-M) for relapsed/refractory metastatic colorectal cancer. Fast Track status accelerates the development and review process for this conditionally activated biologic.
Outcome Details
FDA granted Fast Track designation
Importance:6/10
Sentiment:
0.70
FDAFast Track DesignationOncologyColorectal CancerMasked biologics
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on August 27, 2026 9:08 PM